TORONTO, Sept 24 (Reuters) - Two California legislators have asked U.S. authorities to re-examine a proposed $3.3 billion merger between U.S.-based Valeant Pharmaceuticals International (VRX.N) and Canada’s Biovail Corp (BVF.TO), days before shareholders are to vote on the deal.
